NO20091888L - Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav - Google Patents

Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Info

Publication number
NO20091888L
NO20091888L NO20091888A NO20091888A NO20091888L NO 20091888 L NO20091888 L NO 20091888L NO 20091888 A NO20091888 A NO 20091888A NO 20091888 A NO20091888 A NO 20091888A NO 20091888 L NO20091888 L NO 20091888L
Authority
NO
Norway
Prior art keywords
disorders
compounds
disease
formula
central nervous
Prior art date
Application number
NO20091888A
Other languages
English (en)
Other versions
NO332293B1 (no
Inventor
Michel Cheve
Arielle Genevois-Borella
Gary Maurice Dull
Craig H Miller
Jeffrey Daniel Schmitt
Marc Capet
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20091888L publication Critical patent/NO20091888L/no
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO332293B1 publication Critical patent/NO332293B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nye vinylazacykloalkan-forbindelser med formel (I) er beskrevet. Forbindelsene er ligander for forskjellige nAChR. Forbindelsene og deres farmasøytisk akseptable salter kan anvendes for å fremstille farmasøytiske preparater og/eller medikamenter ment for å forhindre eller behandle lidelser forbundet med dysfunksjon av nAChR, spesielt innen sentralnervesystemet eller mave-tarm-systemet. Eksempler på typer av lidelser som kan behandles omfatter neurodegenerative lidelser, omfattende sentralnervesystem-lidelser så som Alzheimer's sykdom, kognitive lidelser, motoriske lidelser så som Parkinson's sykdom, medikament-avhengighet, adferdsmessige lidelser og inflammatoriske lidelser i mave-tarm-systemet. Forbindelsene kan også tjene som smertestillende midler ved behandling av akutt, kronisk eller tilbakevendende smerte. Formel I
NO20091888A 2003-03-05 2009-05-14 Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom NO332293B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
PCT/US2004/006530 WO2004078752A1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (2)

Publication Number Publication Date
NO20091888L true NO20091888L (no) 2005-10-03
NO332293B1 NO332293B1 (no) 2012-08-20

Family

ID=32926772

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054120A NO331920B1 (no) 2003-03-05 2005-09-05 Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling
NO20091888A NO332293B1 (no) 2003-03-05 2009-05-14 Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom
NO20092231A NO20092231L (no) 2003-03-05 2009-06-09 Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20054120A NO331920B1 (no) 2003-03-05 2005-09-05 Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20092231A NO20092231L (no) 2003-03-05 2009-06-09 Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Country Status (32)

Country Link
US (8) US7098331B2 (no)
EP (3) EP2085395B1 (no)
JP (3) JP4663627B2 (no)
KR (4) KR20120014236A (no)
CN (3) CN101550132B (no)
AR (3) AR043469A1 (no)
AT (3) ATE517893T1 (no)
AU (3) AU2004217903B2 (no)
BR (1) BRPI0409576A (no)
CA (1) CA2516514C (no)
CL (1) CL2004000452A1 (no)
CY (2) CY1110391T1 (no)
DE (2) DE602004031165D1 (no)
DK (2) DK1601670T3 (no)
EA (3) EA014714B1 (no)
ES (3) ES2309507T3 (no)
GT (1) GT200400033A (no)
HK (3) HK1084949A1 (no)
IL (3) IL170155A (no)
JO (1) JO2488B1 (no)
MX (1) MXPA05009386A (no)
NO (3) NO331920B1 (no)
NZ (1) NZ541795A (no)
PA (1) PA8597201A1 (no)
PE (1) PE20040930A1 (no)
PL (5) PL2085395T3 (no)
PT (2) PT1601670E (no)
SI (2) SI2085395T1 (no)
TW (3) TWI339662B (no)
UY (1) UY28218A1 (no)
WO (1) WO2004078752A1 (no)
ZA (1) ZA200506790B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2296640A1 (en) * 2008-05-12 2011-03-23 Targacept Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010065443A1 (en) * 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
KR20120061047A (ko) * 2009-06-17 2012-06-12 타가셉트 인코포레이티드 신경원성 니코틴 수용체 리간드에 의한 ｌ?도파?유도 운동 장애의 역전
MX2012006484A (es) 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
CA2792157A1 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
EP3439661B1 (en) 2016-04-07 2021-08-04 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ATE491689T1 (de) 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02002115A (es) 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
AU780492B2 (en) 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
US8633222B2 (en) 2014-01-21
JP5537085B2 (ja) 2014-07-02
JP5537084B2 (ja) 2014-07-02
CY1111615T1 (el) 2015-10-07
US20060094732A1 (en) 2006-05-04
US20140107164A1 (en) 2014-04-17
DK2085395T3 (da) 2011-04-18
PL2085395T3 (pl) 2011-05-31
AU2008258188A1 (en) 2009-01-15
PE20040930A1 (es) 2005-02-18
IL197889A (en) 2013-03-24
UY28218A1 (es) 2005-06-30
KR20090021228A (ko) 2009-02-27
NZ541795A (en) 2008-03-28
JP2006519868A (ja) 2006-08-31
KR20120014236A (ko) 2012-02-16
US8063068B2 (en) 2011-11-22
EA200501425A1 (ru) 2006-02-24
AU2008258187B2 (en) 2010-08-05
HK1130254A1 (en) 2009-12-24
NO20092231L (no) 2005-10-03
EA200900706A1 (ru) 2009-10-30
PL215059B1 (pl) 2013-10-31
SI2085395T1 (sl) 2011-05-31
US7714001B2 (en) 2010-05-11
WO2004078752A1 (en) 2004-09-16
EP1601670A1 (en) 2005-12-07
EP2085395A1 (en) 2009-08-05
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
PL216979B1 (pl) 2014-06-30
NO20054120D0 (no) 2005-09-05
KR20090021227A (ko) 2009-02-27
ATE517893T1 (de) 2011-08-15
AU2008258187A1 (en) 2009-01-15
AR043469A1 (es) 2005-07-27
KR100953150B1 (ko) 2010-04-19
EP1947100A1 (en) 2008-07-23
CN101550132A (zh) 2009-10-07
NO20054120L (no) 2005-10-03
US7098331B2 (en) 2006-08-29
JP4663627B2 (ja) 2011-04-06
US20080293778A1 (en) 2008-11-27
ATE394394T1 (de) 2008-05-15
PL1601670T3 (pl) 2008-10-31
JP2010001296A (ja) 2010-01-07
ES2385941T3 (es) 2012-08-03
TWI377204B (en) 2012-11-21
GT200400033A (es) 2005-05-29
EA019240B1 (ru) 2014-02-28
ES2389106T3 (es) 2012-10-23
HK1116800A1 (en) 2009-01-02
JO2488B1 (en) 2009-10-05
BRPI0409576A (pt) 2006-04-18
PL394600A1 (pl) 2011-07-18
NO331920B1 (no) 2012-04-30
ZA200506790B (en) 2006-05-31
CN1756754A (zh) 2006-04-05
AU2004217903A1 (en) 2004-09-16
CL2004000452A1 (es) 2005-05-20
TWI339662B (en) 2011-04-01
EA014714B1 (ru) 2011-02-28
EA010870B1 (ru) 2008-12-30
KR101185541B1 (ko) 2012-09-24
CA2516514A1 (en) 2004-09-16
PL378415A1 (pl) 2006-04-03
TW200505909A (en) 2005-02-16
PL394604A1 (pl) 2011-07-18
US20100267776A1 (en) 2010-10-21
KR101018083B1 (ko) 2011-03-02
DE602004031165D1 (de) 2011-03-03
TW200927746A (en) 2009-07-01
KR20060006006A (ko) 2006-01-18
US20110152293A1 (en) 2011-06-23
PT1601670E (pt) 2008-07-11
SI1601670T1 (sl) 2008-10-31
AR070570A2 (es) 2010-04-21
DK1601670T3 (da) 2008-08-25
US20040176348A1 (en) 2004-09-09
US8067443B2 (en) 2011-11-29
EP2085395B1 (en) 2011-01-19
ES2309507T3 (es) 2008-12-16
MXPA05009386A (es) 2005-11-04
AU2008258188B2 (en) 2011-02-24
PA8597201A1 (es) 2004-09-28
CN101550132B (zh) 2012-03-28
CN101255155A (zh) 2008-09-03
NO332293B1 (no) 2012-08-20
IL170155A (en) 2013-08-29
IL197890A (en) 2013-11-28
EP1947100B1 (en) 2011-07-27
EA200801764A1 (ru) 2008-12-30
US20100010042A1 (en) 2010-01-14
AU2004217903B2 (en) 2010-03-04
EP1601670B1 (en) 2008-05-07
ATE496046T1 (de) 2011-02-15
CA2516514C (en) 2012-02-07
CN100526308C (zh) 2009-08-12
US20150164894A1 (en) 2015-06-18
DE602004013553D1 (de) 2008-06-19
JP2009292825A (ja) 2009-12-17
PT2085395E (pt) 2011-04-20
TW200927745A (en) 2009-07-01
HK1084949A1 (en) 2006-08-11

Similar Documents

Publication Publication Date Title
NO20091888L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
WO2001060826A3 (en) SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
PL398445A1 (pl) Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
DE69912808D1 (de) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
TW200502221A (en) Novel lactams and uses thereof
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
MA29722B1 (fr) Schema posologique pour le prasugrel
MX2008002065A (es) Derivados de pirazola como agentes terapeuticos.
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
WO2005042561A3 (en) Neural regeneration peptides and methods of use
MXPA06000193A (es) Derivados de imidazol iii.
ATE496050T1 (de) Neue chinuklidinderivative und deren pharmazeutische verwendung
JP2002371012A (ja) プリオン病の薬のつくりかた
TH104388B (th) รูปผลึกแบบใหม่ของกรด 8-ไซยาโน-1-ไซโคลโพรพิล-7-(1s,6s-2,8-ไดอะซาไบไซโคล[4.3.0] โนแนน-8-อิล)-6-ฟลูออโร-1,4-ไดไฮโดร-4-ไดไฮโดร-4-ออกโซ-3-ควิโนลีนคาร์บอกซิลิก
TH128677A (th) สารประกอบเอริลไวนิลอะซาไซโคลอัลเคน และวิธีการเตรียมและการใช้ของสาร
WO2008020256A3 (en) 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees